Effect of antifibrotics on short-term outcome after bilateral lung transplantation: a multicentre analysis
Interstitial lung diseases (ILDs) are a heterogeneous entity of diffuse parenchymal lung diseases characterised by damage of the parenchyma as a result of varying patterns of inflammation and fibrosis [1]. Idiopathic pulmonary fibrosis (IPF) is a specific subgroup of ILDs and has a devastating progn...
Gespeichert in:
| Veröffentlicht in: | The European respiratory journal 2018-06, Vol.51 (6), p.1800503-1800503 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1800503 |
|---|---|
| container_issue | 6 |
| container_start_page | 1800503 |
| container_title | The European respiratory journal |
| container_volume | 51 |
| creator | Lambers, Christopher Boehm, Panja M Lee, Silvia Ius, Fabio Jaksch, Peter Klepetko, Walter Tudorache, Igor Ristl, Robin Welte, Tobias Gottlieb, Jens |
| description | Interstitial lung diseases (ILDs) are a heterogeneous entity of diffuse parenchymal lung diseases characterised by damage of the parenchyma as a result of varying patterns of inflammation and fibrosis [1]. Idiopathic pulmonary fibrosis (IPF) is a specific subgroup of ILDs and has a devastating prognosis [2] with a median survival time of 2–3 years [2–4]. Pirfenidone (Esbriet) and nintedanib (Ofev) were approved for IPF treatment, showing a stabilisation of the disease [5, 6], and are the treatments recommended by international guidelines [1]. Nintedanib was shown to increase the risk of bleeding events in IPF patients during therapy [7] and the European Medicines Agency recommended discontinuation of nintedanib before major surgery but without a definite time frame for discontinuation [8]. Corticosteroids have been the conventional strategy used as treatment in different ILD subtypes despite limited evidence regarding their efficacy [9, 10]. After failure of medical therapy in severe ILD, lung transplantation (LuTx) represents an established therapeutic option in order to improve quality of life and survival [11]. |
| doi_str_mv | 10.1183/13993003.00503-2018 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2028952871</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2070110970</sourcerecordid><originalsourceid>FETCH-LOGICAL-c378t-53fba61ee6809b8b9d3b8238f5259c401d899ecf8afd50eb880fa120b480f5983</originalsourceid><addsrcrecordid>eNpdkc1OwzAQhC0EoqXwBEjIEhcuKWu7SWxuqCo_UiUucI7sxAZXSVxs59C3x6EtB05rj74ZrXYQuiYwJ4Sze8KEYABsDpADyygQfoKmo5qN8imagkg6EayYoIsQNgCkWDByjiZUFCUXCzpFm5Uxuo7YGSz7aI1V3kVbB-x6HL6cj1nUvsNuiLXrNJYmfbGyrUxTtrgd-k8cvezDtk1-Ga3rH7DE3dCmFN1Hnzy9bHfBhkt0ZmQb9NVhztDH0-p9-ZKt355fl4_rrGYlj1nOjJIF0brgIBRXomGKU8ZNTnNRL4A0XAhdGy5Nk4NWnIORhIJapEcuOJuhu33u1rvvQYdYdTbUuk0LajeEigLlIqe8JAm9_Ydu3ODTviNVAiEgSkgU21O1dyF4baqtt530u4pANVZRHauofquoxiqS6-aQPahON3-e4-3ZD0wLhNA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2070110970</pqid></control><display><type>article</type><title>Effect of antifibrotics on short-term outcome after bilateral lung transplantation: a multicentre analysis</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Lambers, Christopher ; Boehm, Panja M ; Lee, Silvia ; Ius, Fabio ; Jaksch, Peter ; Klepetko, Walter ; Tudorache, Igor ; Ristl, Robin ; Welte, Tobias ; Gottlieb, Jens</creator><creatorcontrib>Lambers, Christopher ; Boehm, Panja M ; Lee, Silvia ; Ius, Fabio ; Jaksch, Peter ; Klepetko, Walter ; Tudorache, Igor ; Ristl, Robin ; Welte, Tobias ; Gottlieb, Jens</creatorcontrib><description>Interstitial lung diseases (ILDs) are a heterogeneous entity of diffuse parenchymal lung diseases characterised by damage of the parenchyma as a result of varying patterns of inflammation and fibrosis [1]. Idiopathic pulmonary fibrosis (IPF) is a specific subgroup of ILDs and has a devastating prognosis [2] with a median survival time of 2–3 years [2–4]. Pirfenidone (Esbriet) and nintedanib (Ofev) were approved for IPF treatment, showing a stabilisation of the disease [5, 6], and are the treatments recommended by international guidelines [1]. Nintedanib was shown to increase the risk of bleeding events in IPF patients during therapy [7] and the European Medicines Agency recommended discontinuation of nintedanib before major surgery but without a definite time frame for discontinuation [8]. Corticosteroids have been the conventional strategy used as treatment in different ILD subtypes despite limited evidence regarding their efficacy [9, 10]. After failure of medical therapy in severe ILD, lung transplantation (LuTx) represents an established therapeutic option in order to improve quality of life and survival [11].</description><identifier>ISSN: 0903-1936</identifier><identifier>EISSN: 1399-3003</identifier><identifier>DOI: 10.1183/13993003.00503-2018</identifier><identifier>PMID: 29678942</identifier><language>eng</language><publisher>England: European Respiratory Society Journals Ltd</publisher><subject>Corticosteroids ; Europe ; Female ; Fibrosis ; Humans ; Indoles - therapeutic use ; Lung diseases ; Lung Diseases, Interstitial - mortality ; Lung Diseases, Interstitial - therapy ; Lung transplantation ; Lung Transplantation - methods ; Male ; Medical prognosis ; Middle Aged ; Parenchyma ; Postoperative Care ; Pyridones - therapeutic use ; Quality of life ; Retrospective Studies ; Steroids - therapeutic use ; Surgery ; Survival ; Treatment Outcome</subject><ispartof>The European respiratory journal, 2018-06, Vol.51 (6), p.1800503-1800503</ispartof><rights>Copyright European Respiratory Society Journals Ltd. Jun 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c378t-53fba61ee6809b8b9d3b8238f5259c401d899ecf8afd50eb880fa120b480f5983</citedby><cites>FETCH-LOGICAL-c378t-53fba61ee6809b8b9d3b8238f5259c401d899ecf8afd50eb880fa120b480f5983</cites><orcidid>0000-0002-7762-5477</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29678942$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lambers, Christopher</creatorcontrib><creatorcontrib>Boehm, Panja M</creatorcontrib><creatorcontrib>Lee, Silvia</creatorcontrib><creatorcontrib>Ius, Fabio</creatorcontrib><creatorcontrib>Jaksch, Peter</creatorcontrib><creatorcontrib>Klepetko, Walter</creatorcontrib><creatorcontrib>Tudorache, Igor</creatorcontrib><creatorcontrib>Ristl, Robin</creatorcontrib><creatorcontrib>Welte, Tobias</creatorcontrib><creatorcontrib>Gottlieb, Jens</creatorcontrib><title>Effect of antifibrotics on short-term outcome after bilateral lung transplantation: a multicentre analysis</title><title>The European respiratory journal</title><addtitle>Eur Respir J</addtitle><description>Interstitial lung diseases (ILDs) are a heterogeneous entity of diffuse parenchymal lung diseases characterised by damage of the parenchyma as a result of varying patterns of inflammation and fibrosis [1]. Idiopathic pulmonary fibrosis (IPF) is a specific subgroup of ILDs and has a devastating prognosis [2] with a median survival time of 2–3 years [2–4]. Pirfenidone (Esbriet) and nintedanib (Ofev) were approved for IPF treatment, showing a stabilisation of the disease [5, 6], and are the treatments recommended by international guidelines [1]. Nintedanib was shown to increase the risk of bleeding events in IPF patients during therapy [7] and the European Medicines Agency recommended discontinuation of nintedanib before major surgery but without a definite time frame for discontinuation [8]. Corticosteroids have been the conventional strategy used as treatment in different ILD subtypes despite limited evidence regarding their efficacy [9, 10]. After failure of medical therapy in severe ILD, lung transplantation (LuTx) represents an established therapeutic option in order to improve quality of life and survival [11].</description><subject>Corticosteroids</subject><subject>Europe</subject><subject>Female</subject><subject>Fibrosis</subject><subject>Humans</subject><subject>Indoles - therapeutic use</subject><subject>Lung diseases</subject><subject>Lung Diseases, Interstitial - mortality</subject><subject>Lung Diseases, Interstitial - therapy</subject><subject>Lung transplantation</subject><subject>Lung Transplantation - methods</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Parenchyma</subject><subject>Postoperative Care</subject><subject>Pyridones - therapeutic use</subject><subject>Quality of life</subject><subject>Retrospective Studies</subject><subject>Steroids - therapeutic use</subject><subject>Surgery</subject><subject>Survival</subject><subject>Treatment Outcome</subject><issn>0903-1936</issn><issn>1399-3003</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkc1OwzAQhC0EoqXwBEjIEhcuKWu7SWxuqCo_UiUucI7sxAZXSVxs59C3x6EtB05rj74ZrXYQuiYwJ4Sze8KEYABsDpADyygQfoKmo5qN8imagkg6EayYoIsQNgCkWDByjiZUFCUXCzpFm5Uxuo7YGSz7aI1V3kVbB-x6HL6cj1nUvsNuiLXrNJYmfbGyrUxTtrgd-k8cvezDtk1-Ga3rH7DE3dCmFN1Hnzy9bHfBhkt0ZmQb9NVhztDH0-p9-ZKt355fl4_rrGYlj1nOjJIF0brgIBRXomGKU8ZNTnNRL4A0XAhdGy5Nk4NWnIORhIJapEcuOJuhu33u1rvvQYdYdTbUuk0LajeEigLlIqe8JAm9_Ydu3ODTviNVAiEgSkgU21O1dyF4baqtt530u4pANVZRHauofquoxiqS6-aQPahON3-e4-3ZD0wLhNA</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Lambers, Christopher</creator><creator>Boehm, Panja M</creator><creator>Lee, Silvia</creator><creator>Ius, Fabio</creator><creator>Jaksch, Peter</creator><creator>Klepetko, Walter</creator><creator>Tudorache, Igor</creator><creator>Ristl, Robin</creator><creator>Welte, Tobias</creator><creator>Gottlieb, Jens</creator><general>European Respiratory Society Journals Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7762-5477</orcidid></search><sort><creationdate>20180601</creationdate><title>Effect of antifibrotics on short-term outcome after bilateral lung transplantation: a multicentre analysis</title><author>Lambers, Christopher ; Boehm, Panja M ; Lee, Silvia ; Ius, Fabio ; Jaksch, Peter ; Klepetko, Walter ; Tudorache, Igor ; Ristl, Robin ; Welte, Tobias ; Gottlieb, Jens</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c378t-53fba61ee6809b8b9d3b8238f5259c401d899ecf8afd50eb880fa120b480f5983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Corticosteroids</topic><topic>Europe</topic><topic>Female</topic><topic>Fibrosis</topic><topic>Humans</topic><topic>Indoles - therapeutic use</topic><topic>Lung diseases</topic><topic>Lung Diseases, Interstitial - mortality</topic><topic>Lung Diseases, Interstitial - therapy</topic><topic>Lung transplantation</topic><topic>Lung Transplantation - methods</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Parenchyma</topic><topic>Postoperative Care</topic><topic>Pyridones - therapeutic use</topic><topic>Quality of life</topic><topic>Retrospective Studies</topic><topic>Steroids - therapeutic use</topic><topic>Surgery</topic><topic>Survival</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lambers, Christopher</creatorcontrib><creatorcontrib>Boehm, Panja M</creatorcontrib><creatorcontrib>Lee, Silvia</creatorcontrib><creatorcontrib>Ius, Fabio</creatorcontrib><creatorcontrib>Jaksch, Peter</creatorcontrib><creatorcontrib>Klepetko, Walter</creatorcontrib><creatorcontrib>Tudorache, Igor</creatorcontrib><creatorcontrib>Ristl, Robin</creatorcontrib><creatorcontrib>Welte, Tobias</creatorcontrib><creatorcontrib>Gottlieb, Jens</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The European respiratory journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lambers, Christopher</au><au>Boehm, Panja M</au><au>Lee, Silvia</au><au>Ius, Fabio</au><au>Jaksch, Peter</au><au>Klepetko, Walter</au><au>Tudorache, Igor</au><au>Ristl, Robin</au><au>Welte, Tobias</au><au>Gottlieb, Jens</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of antifibrotics on short-term outcome after bilateral lung transplantation: a multicentre analysis</atitle><jtitle>The European respiratory journal</jtitle><addtitle>Eur Respir J</addtitle><date>2018-06-01</date><risdate>2018</risdate><volume>51</volume><issue>6</issue><spage>1800503</spage><epage>1800503</epage><pages>1800503-1800503</pages><issn>0903-1936</issn><eissn>1399-3003</eissn><abstract>Interstitial lung diseases (ILDs) are a heterogeneous entity of diffuse parenchymal lung diseases characterised by damage of the parenchyma as a result of varying patterns of inflammation and fibrosis [1]. Idiopathic pulmonary fibrosis (IPF) is a specific subgroup of ILDs and has a devastating prognosis [2] with a median survival time of 2–3 years [2–4]. Pirfenidone (Esbriet) and nintedanib (Ofev) were approved for IPF treatment, showing a stabilisation of the disease [5, 6], and are the treatments recommended by international guidelines [1]. Nintedanib was shown to increase the risk of bleeding events in IPF patients during therapy [7] and the European Medicines Agency recommended discontinuation of nintedanib before major surgery but without a definite time frame for discontinuation [8]. Corticosteroids have been the conventional strategy used as treatment in different ILD subtypes despite limited evidence regarding their efficacy [9, 10]. After failure of medical therapy in severe ILD, lung transplantation (LuTx) represents an established therapeutic option in order to improve quality of life and survival [11].</abstract><cop>England</cop><pub>European Respiratory Society Journals Ltd</pub><pmid>29678942</pmid><doi>10.1183/13993003.00503-2018</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-7762-5477</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0903-1936 |
| ispartof | The European respiratory journal, 2018-06, Vol.51 (6), p.1800503-1800503 |
| issn | 0903-1936 1399-3003 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2028952871 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Corticosteroids Europe Female Fibrosis Humans Indoles - therapeutic use Lung diseases Lung Diseases, Interstitial - mortality Lung Diseases, Interstitial - therapy Lung transplantation Lung Transplantation - methods Male Medical prognosis Middle Aged Parenchyma Postoperative Care Pyridones - therapeutic use Quality of life Retrospective Studies Steroids - therapeutic use Surgery Survival Treatment Outcome |
| title | Effect of antifibrotics on short-term outcome after bilateral lung transplantation: a multicentre analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T17%3A58%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20antifibrotics%20on%20short-term%20outcome%20after%20bilateral%20lung%20transplantation:%20a%20multicentre%20analysis&rft.jtitle=The%20European%20respiratory%20journal&rft.au=Lambers,%20Christopher&rft.date=2018-06-01&rft.volume=51&rft.issue=6&rft.spage=1800503&rft.epage=1800503&rft.pages=1800503-1800503&rft.issn=0903-1936&rft.eissn=1399-3003&rft_id=info:doi/10.1183/13993003.00503-2018&rft_dat=%3Cproquest_cross%3E2070110970%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2070110970&rft_id=info:pmid/29678942&rfr_iscdi=true |